Physician profile
Rohitha Inturi
NPI 1669762167
$1,928.36
in general payments reported to CMS, 2019-2025
24 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.41 · 2020: $30.13 · 2022: $241 · 2023: $695 · 2024: $649 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,530 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,530.22 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $243.79 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $226.34 | 2023-2025 | |
| Pfizer INC. | $186.89 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $150.73 | 2020-2025 | Spravato |
| Astellas Pharma US INC | $141.30 | 2023-2024 | Veozah |
| Novo Nordisk INC | $134.18 | 2020-2024 | Wegovy, Rybelsus, Ozempic |
| Dexcom, INC. | $121.96 | 2022-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $103.86 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $103.77 | 2023-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $97.05 | 2019-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.54 | 2023-2024 | Jardiance, Tradjenta, Synjardy |
| Sanofi-Aventis U.S. LLC | $46.19 | 2022-2025 | |
| Nevro Corp. | $40.49 | 2019-2023 | Senza |
| Medtronic, INC. | $34.39 | 2022 | |
| Idorsia Pharmaceuticals US INC | $32.71 | 2023 | Quviviq |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $28.24 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.95 | 2025 | Caplyta |
| Corcept Therapeutics | $23.25 | 2024 | Korlym |
| Ultragenyx Pharmaceutical INC. | $21.90 | 2022 | |
| Lundbeck LLC | $21.70 | 2024 | Rexulti |
| Edwards Lifesciences Corporation | $20.39 | 2022 | |
| Abbott Laboratories | $16.11 | 2023 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $14.47 | 2024 | Onzetra Xsail, Contrave |
| Amgen INC. | $13.16 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohitha Inturi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.